The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFrontier Ip Regulatory News (FIPP)

Share Price Information for Frontier Ip (FIPP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 41.50
Bid: 40.00
Ask: 43.00
Change: 0.50 (1.22%)
Spread: 3.00 (7.50%)
Open: 41.50
High: 41.50
Low: 41.50
Prev. Close: 41.00
FIPP Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Topps Tiles launches first Alusid made tile range

9 May 2023 07:00

RNS Number : 6470Y
Frontier IP Group plc
09 May 2023
 

Reach - a non-regulatory announcement

AIM: FIPP

09 May 2023

 

Frontier IP Group Plc

("Frontier IP" or the "Group")

 

 

Portfolio news - Topps Tiles launches first Alusid-made wall tile range

 

 

Frontier IP, a specialist in commercialising intellectual property, today announces that portfolio company Alusid Limited ("Alusid" or the "Company") has launched its first range of mass-produced wall tiles made from its sustainable materials with Topps Tiles, the retail arm of Topps Tiles Plc (or "Topps Group"), the UK's no.1 tile specialist.

 

A first range of wall tiles has already been launched exclusively in UK retail by Topps Tiles and is now available in four colours online and in store. Called Principle, the tiles are made on industry-standard mass production equipment from a minimum of 91 per cent recycled industrial waste, one of the highest levels in the global tile industry.

 

The industrial waste used includes tile dust, tableware production sludge, glass and ceramics and much of this has no other use and is sent to landfill. Using recycled material also means fewer raw materials, such as clay, feldspar and quartz, need to be mined. Each square metre of Principle tiling saves 8kg of waste from landfill and 14kg of raw material from extraction.

 

Because Alusid's patented recipes and methods remove processing stages during manufacture, the Principle tiles are made using 23 per cent less gas during production than the processes used to make the equivalent type of tile.

 

Alusid's products have attracted significant industry interest. Following a collaboration with Imerys, a global leader in speciality minerals, the Company is now trialling mass production of hard-wearing floor tiles, which comprise some 60 per cent of the total tile market in the UK, according to MTW Research.

 

As well as Topps Tiles, customers of Alusid include Starbucks, Pret a Manger, H&M, the BBC and the Stonehenge Visitor Centre, run by English Heritage. The Topps Tiles agreement builds on the existing relationship with Parkside, the commercial arm of Topps Group, which is also selling Principle and a hand-made range, Sequel.

 

Frontier IP holds a 37.5 per cent equity stake in the Company.

 

 

Tim Tatlock, Buying Director Topps Tiles, said: "The Alusid-made Principle range combines high-quality and good looks with a level of recycled content among the highest in the industry. We believe they will prove popular with our customers. Backing innovative suppliers, such as Alusid, to support recycling and circularity, is an important part of our goals to achieve environmental leadership in the sector and our aim to be carbon neutral in 2030 with regards to scope 1 and 2 as set out in the Greenhouse Gas Protocol. This is only the start of our relationship with Alusid, and we look forward to developing new products with the company in the years to come."

 

Alasdair Bremner, Alusid's CEO said: "The launch of Principle with Topps Tiles is a huge step forward for Alusid into mass production and scalability and is the result of many years hard work from our team. We're excited about the potential this unique partnership with the UK's leading tile retailer holds in the coming years, and to working with the company to reduce the environmental impact of the ceramic tile industry."

 

Frontier IP Chief Executive Neil Crabb said: "Alusid's agreement with Topps Tiles represents strong validation of the Company's technology and the high quality of the tiles produced - and at industrial scale. We are very excited by the company's potential, given the size of the global tile market, successful trials of mass-made floor tiles and the unique nature of the patented technology."

 

 

ENQUIRIES

 

 

Frontier IP Group Plc

T: 020 7332 2338

Neil Crabb, Chief Executive

Andrew Johnson, Communications & Investor Relations

Company website: www.frontierip.co.uk

neil@frontierip.co.uk

M: 07464 546 025

Allenby Capital Limited (Nominated Adviser)

Nick Athanas / George Payne

 

T: 0203 328 5656

 

 

 

 

ABOUT TOPPS GROUP

Topps Tiles' retail omni-channel brand is the UK's number one tile specialist with more than 300 stores across the UK. The brand has seen another record-breaking sales year alongside a customer sentiment growth of 1.2% (now averaging a leading OSAT score of over 90%) and a market share of 19%. The brand is firmly on track to reach the Group's strategic goal of 1 in 5 by 2025 whilst working to become carbon neutral by 2030.

For more information, please visit http://www.toppstiles.co.uk.

 

 

ABOUT ALUSID

Alusid creates beautiful, premium-quality tiles and architectural surfaces by recycling industrial waste ceramics, glass and other materials much of which would otherwise end in landfill.

 

The company's Sequel ranges are distributed exclusively by Parkside Architectural Tiles, the commercial arm of Topps Tiles. Sequel Vibe was named Wall Tile of The Year in The Tile Association's prestigious awards in 2020.

 

Alusid also makes its own products under the brand name SilicaStone distributed in the UK by Panaz. Customers include COS, part of H&M, Christian Dior, Nando's, Harrods, Selfridges, Amazon UK and Pret-a-Manger.

 

ABOUT FRONTIER IP

Frontier IP unites science and commerce by identifying strong intellectual property and accelerating its development through a range of commercialisation services. A critical part of the Group's work is involving relevant industry partners at an early stage of development to ensure technology meets real world demands and needs.

The Group looks to build and grow a portfolio of equity stakes and licence income by taking an active involvement in spin-out companies, including support for fund raising and collaboration with relevant industry partners at an early stage of development.

 

About Reach announcements

This is a Reach announcement. Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases into the public domain. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on Reach.

 

 

 

 

 

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRABLGDUSXGDGXU
Date   Source Headline
2nd Dec 20227:00 amRNSThe Vaccine Group completes vaccine project
30th Nov 20225:00 pmRNSTotal Voting Rights
25th Nov 20222:23 pmRNSDirector/PDMR Shareholding
23rd Nov 20225:17 pmRNSDirector share transfers
18th Nov 20223:53 pmRNSExercise of Options & PDMR Shareholdings
11th Nov 20223:07 pmRNSDirector/PDMR Dealing
11th Nov 20227:00 amRNSPosting of Annual Report and Notice of AGM
8th Nov 20227:00 amRNSPulsiv announces £1.5m fundraise
1st Nov 20221:46 pmEQSFrontier IP Group 'rigged for a storm' but confident of more progress
27th Oct 20227:00 amRNSFinal Results
19th Oct 20224:22 pmRNSHolding(s) in Company
19th Oct 20223:29 pmRNSHolding(s) in Company
14th Oct 20227:00 amRNSElute Intelligence appoints Steve Cable as CEO
27th Sep 20227:00 amRNSPulsiv unveils power electronics technology
18th Aug 20223:20 pmRNSSale of shares in Exscientia
5th Aug 20227:00 amRNSCamGraPhIC announces £1.26 million fundraising
26th Jul 20224:26 pmRNSHolding(s) in Company
26th Jul 20224:07 pmRNSHolding(s) in Company
24th May 20227:00 amRNSCambridge Raman Imaging raises £1.1 million
19th May 20227:00 amRNSPublication of newsletter
12th Apr 20225:18 pmRNSHolding(s) in Company
17th Mar 20227:00 amRNSUnaudited Half Year Results
14th Feb 20227:00 amRNSSale of shares in Exscientia
11th Feb 20225:04 pmRNSHolding(s) in Company
11th Feb 20222:05 pmRNSHolding(s) in Company
10th Feb 20227:00 amRNSCambridge Raman Imaging wins European Union grant
25th Jan 20227:00 amRNSSale of shares in Exscientia
17th Jan 20225:56 pmRNSHolding(s) in Company
12th Jan 20227:00 amRNSTrading update
11th Jan 20227:00 amRNSCelerum launch first commercial product
9th Dec 20212:33 pmRNSResult of AGM
29th Nov 20217:00 amRNSTVG - milestone in development of COVID-19 vaccine
9th Nov 20217:00 amRNSPosting of Annual Accounts and Notice of AGM
28th Oct 20217:00 amRNSDirectorate Change
28th Oct 20217:00 amRNSFinal Results
15th Oct 20217:00 amRNSPublication of newsletter
1st Oct 20217:59 amRNSPricing of IPO of Exscientia in the United States
30th Sep 20217:00 amRNSCamGraPhIC raises £1.6 million
27th Sep 20213:56 pmRNSUpdate on proposed IPO of Exscientia
24th Sep 20217:00 amRNSHolding(s) in Company
13th Sep 20217:00 amRNSExscientia - Statement filed for proposed IPO
8th Sep 20211:24 pmRNSExscientia enters $70M collaboration
8th Jul 20217:00 amRNSCamGraPhIC loan facility of up to £1.5 million
15th Jun 20217:00 amRNSPulsiv appoints Adam Westcott as CFO
14th Jun 20217:00 amRNSNandi Proteins appoints David Flower as CEO
11th Jun 20217:00 amRNSPublication of newsletter
24th May 20217:00 amRNSPulsiv complete £1.5m fundraising and appoints CEO
19th May 202111:53 amRNSExscientia collaboration with Bristol Myers Squibb
6th May 20217:00 amRNSThe Vaccine Group appoints Jeremy Salt as CEO
30th Apr 20211:58 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.